

10/532667

JC13 Rec'd PCT/PTO 27 APR 2005  
X2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of :  
Yu MOMOSE et al.

: Mail Stop: PCT  
Serial No. NEW : Attorney Docket No. 2005\_0727A

Filed April 27, 2005 :

AGENT FOR PREVENTING OR TREATING  
NEUROPATHY

[Corresponding to PCT/JP2003/013901  
Filed October 30, 2003]

---

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the provisions of 37 CFR 1.56, 1.97 and 1.98, Applicants request consideration of the references listed on attached form PTO-1449 and any additional information identified below in paragraph 3. A legible copy of each reference listed on the Form PTO-1449 is enclosed, except a copy is not provided for:

- each U.S. Patent and U.S. Patent application publication;
- each reference previously cited in the international application  
PCT/JP2003/013901; and/or
- each reference previously cited in prior parent application Serial No.

1a.  This Information Disclosure Statement is submitted:

within three months of the filing date (or of entry into the National Stage) of the above-entitled application, or

before the mailing of a first Office Action on the merits or the mailing of a first Office Action after the filing of an RCE,

**and thus no certification and/or fee is required.**

- 1b.  This Information Disclosure Statement is submitted  
after the events of above paragraph 1a and prior to the mailing date of a final Office Action or a Notice of Allowance or an action which otherwise closes prosecution in the application, and thus:  
(1)  the certification of paragraph 2 below is provided, **or**  
(2)  the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.

- 1c.  This Information Disclosure Statement is submitted:  
after the mailing date of a final Office Action or Notice of Allowance or action which otherwise closes prosecution in the application, and prior to payment of the issue fee, and thus:  
**the certification of paragraph 2 below is provided, and**  
**the fee of \$180.00 specified in 37 CFR 1.17(p) is enclosed.**

2. It is hereby certified
- a.  that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Statement, or
  - b.  that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of the Statement.

3.  Consideration of the following list of additional information (including any copending or abandoned U.S. application, prior uses and/or sales, etc.) is requested.
4. For each non-English language reference listed on the attached form PTO-1449, reference is made to:
  - a.  a full or partial English language translation submitted herewith,
  - b.  a foreign patent office search report (in the English language) submitted herewith,
  - c.  the concise explanation contained in the specification of the present application at page,
  - d.  the concise explanation set forth in the attached English language abstract,
  - e.  the concise explanation set forth below or on a separate sheet attached to the reference:
5.  A foreign patent office search report citing one or more of the references is enclosed along with the International Preliminary Examination Report.

Respectfully submitted,

Yu MOMOSE et al.

By Warren M. Cheek, Jr.  
Warren M. Cheek, Jr.  
Registration No. 33,367  
Attorney for Applicants

WMC/dlk  
Washington, D.C. 20006-1021  
Telephone (202) 721-8200  
Facsimile (202) 721-8250  
April 27, 2005

FORM PTO 1449 (modified)

ATTY DOCKET NO.  
2005\_0727ASERIAL NO.  
NEWU.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: April 27, 2005

APPLICANT  
Yu MOMOSE et al.FILING DATE  
April 27, 2005

10/532667

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,464,860	11/1995	Lepage et al.			
	AB	5,250,504	10/1993	Maravetz			
	AC	4,835,280	5/1989	Martens et al.			
	AD	4,172,136	10/1979	Berger et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AE	03/049702	6/2003	WO			
	AE	02/098852	12/2002	WO			
	AG	00/75120	12/2000	WO			
	AH	1 148 053	10/2001	EP			
	AI	0 153 850	9/1985	EP			
	AJ	0 630 894	12/1994	EP			
	AK	86/00307	1/1986	WO			
	AL	00/01679	1/2000	WO			Abstract
	AM	01/14372	3/2001	WO			

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	AN	T. M. Monteiro et al., "Synthesis and analgesic activity of new pyrazole-4-carboxanilides and (E)-3-pyrazol-4-ylpropenylanilides", Revista Portuguesa De Farmacia, Vol. 49, No. 4, 1999, pp. 153-160, with English translation.
	AO	M. K. Bratenko et al., "Functionally Substituted 3-Hetarylpyrazoles: XI. 3-[3-Aryl (hetaryl)pyrazol-4-yl]propenoic and Propanoic Acids", Russian Journal of Organic Chemistry, Vol. 38, No. 8, 2002, pp. 1171-1177.
	AP	Patent Abstracts of Japan, Vol. 1998, No. 12, October 31, 1998 & JP 10 195063 A, July 28, 1998 *abstract*.

EXAMINER

DATE CONSIDERED

FORM PTO 1449 (modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT(S) <i>(Use several sheets if necessary)</i> Date Submitted to PTO: April 27, 2005			ATTY DOCKET NO. 2005_0727A		SERIAL NO. NEW 10/532667		
			APPLICANT Yu MOMOSE et al.				
			FILING DATE April 27, 2005			GROUP	
			U.S. PATENT DOCUMENTS				
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA	3,702,330	11/1972	Hoff et al.			
	BB	2004/0204417	10/2004	Perez et al.			Corresponds to AF
	BC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	BD	4-184435	7/1992	JP			Abstract
	BE	2003/099793	12/2003	WO			
	BF	03/072554	9/2003	WO			Abstract
	BG						
	BH						
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
	BI	M. Ohta et al., "Novel 5-Hydroxytryptamine (5-HT <sub>3</sub> ) Receptor Antagonists. I. Synthesis and Structure-Activity Relationships of Conformationally Restricted Fused Imidazole Derivatives" Chem. Phar. Bull. Vol. 44, No. 5, 1996, pp. 991-999.					
	BJ	Y. Yuen-Lang et al., "Chemotherapeutic Studies on Schistosomiasis XXXIII. Synthesis of β-(5-Nitroimidazol-2-Yl) Acrylamides and Related Compounds", Pharmaceutical Industry, Vol. 17, No. 10, 1986, pp. 444-448, with English translation.					
	BK	Y. Z. Ling et al., "17-Imidazolyl, Pyrazolyl, and Isoxazolyl Androstene Derivatives. Novel Steroidal Inhibitors of Human Cytochrome C <sub>17,20</sub> -Lyase (P450 <sub>17a</sub> )", J. Med. Chem., Vol. 40, No. 20, September 26, 1997, pp. 3297-3304.					
	BL	R. Plate et al., "Synthesis and Muscarinic Activities of 3-(Pyrazolyl)-1,2,5,6-tetrahydropyridine Derivatives", Bioorganic & Medicinal Chemistry, Vol. 4, No. 2, February 1996, pp. 227-237.					
	BM	C. S. Lee et al., "Carbon-Carbon Linked (Pyrazolylphenyl)oxazolidinones with Antibacterial Activity Against Multiple Drug Resistant Gram-Positive and Fastidious Gram-Negative Bacteria", Bioorganic & Medicinal Chemistry, Vol. 9, No. 12, December 2001, pp. 3243-3253.					
	BN	R. Plate et al., "Synthesis and <i>In Vitro</i> Muscarinic Activities of a Series of 3-(Pyrazol-3-yl)-1-azabicyclo[2.2.2]octanes", Bioorganic & Medicinal Chemistry, Vol. 8, No. 2, February 2000, pp. 449-454.					
EXAMINER				DATE CONSIDERED			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JC13 Rec'd PCT/PTO 2 APR 2005

Sheet 3 of 3

## INFORMATION DISCLOSURE STATEMENT

FORM PTO 1449 (modified)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICELIST OF REFERENCES CITED BY APPLICANT(S)  
(Use several sheets if necessary)

Date Submitted to PTO: April 27, 2005

ATTY DOCKET NO.  
2005\_0727ASERIAL NO.  
NEW

10/532667

APPLICANT  
Yu MOMOSE et al.FILING DATE  
April 27, 2005

GROUP

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	CA						
	CB						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	CC						
	CD						
	CE						
	CF						
	CG						

## OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)

	CH	R. W. Harper et al., "Leukotriene B <sub>4</sub> (LTB <sub>4</sub> ) Receptor Antagonists: A Series of (Hydroxyphenyl)pyrazoles", J. Med. Chem., Vol. 37, No. 15, July 22, 1994, pp. 2411-2420.
	CI	G. R. Bebernitz et al., "The Effect of 1,3-Diaryl-[1H]-pyrazole-4-acetamides on Glucose Utilization in ob/ob Mice", J. Med. Chem., Vol. 44, 2001, pp. 2601-2611.
	CJ	
	CK	
	CL	
	CM	

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.